Table 3. Clinical features, diagnosis and treatment details.

Variable	Value (n = 36)
Symptoms Altered higher mental functions(memory defects/altered sensorium) and seizures Cerebrovascular accident like episodes/visual disturbances Headache and dizziness	15 (48.4%) 6 (19.4%) 10 (32.2%)
Diagnosis CSF analysis Imaging CSF analysis and Imaging	10 (27.8%) 18 (50%) 8 (22.2%)
Number of other sites of metastasis 1 2 3	5 (13.8%) 21(58.3%) 10 (27.8%)
Brain metastasis prior to leptomeningeal metastasis Yes No	9 (25%) 27 (75%)
Number of previous lines of therapy 1 2 3	24 (66.6%) 6 (16.7%) 6 (16.7%)
Brain metastasis or progression at the time of leptomeningeal metastasis Yes No	10 (27.8%) 26 (72.2%)
Intrathecal therapy Methotrexate Triple intrathecal therapy	11 (47.8%) 7 (63.6%) 4 (36.45)
Chemotherapy Pemetrexed Docetaxel Paclitaxel	6 (26%) 2 (33.3%) 3 (50%) 1 (16.7%)
Tyrosine kinase inhibitor Erlotinib High Standard Gefitinib High Standard Osimertinib High Standard	18 (78.2%) 3 (16.7%) - 3 (33.3%) 6 (66.7%) 1 (16.7%) 5 (83.3%)